Precision Medicine in Rheumatology (PREMIER) is an NIH/NIAMS funded Center at UCSF with the overarching goal of facilitating and enhancing precision medicine studies in rheumatic diseases
Human Subjects and Clinical Phenotyping Core provides expertise in study design, clinical informatics, and rheumatic diseases to facilitate the identification and recruitment of defined patient groups for research

GMR Core
Genomics and Molecular Resources Core will provide access to biospecimens from rheumatic disease patients and facilitate access to state-of-the-art genomics and cellular molecular technologies
IB Core
Integrative Bioinformatics Core will provide expertise in state-of-the-art computational approaches required for study design, bioinformatics data analysis, data integration, and data dissemination
PREMIER Funding Opportunities
Pilot funds available for junior ($40,000) and established investigators ($50,000)
Applications Launch: Fall Cycle-TBD


PREMIER will provide investigators with access to biospecimens, expertise, training, and pilot funding to advance precision medicine studies in rheumatic diseases.

UCSF is a national leader in the area of precision medicine. PREMIER, Precision Medicine in Rheumatology is an NIH/NIAMS funded Center at UCSF with the overarching goal of facilitating and enhancing precision medicine studies in rheumatic diseases. The development of innovative technologies promises to deliver tests and therapies to patients that will enable us to tailor treatment and limit side effects, however for patients with rheumatic diseases, these studies are only in their infancy. PREMIER can provide investigators with resources to enable studies that will better define rheumatic disease subgroups with different etiologies, prognoses, or treatment responses. Core resources can provide access to clinical data and biospecimens along with new technologies for cellular, molecular and genetic phenotyping and bioinformatics analyses. PREMIER aims to improve approaches to the diagnosis and treatment of rheumatic disease. UCSF represents an ideal environment for the center given tremendous institutional strengths in immunology, genomics, molecular technologies, computational biology, and clinical research, and a track record of engaging both unique disease populations and racial/ethnic minority populations in clinical/translational research. PREMIER will work to attract both new and experienced investigators to investigations into human autoimmunity and support them to conduct breakthrough precision medicine studies focused on the rheumatic diseases. 

Funding Opportunities

PREMIER has several funding opportunities throughout the year, including pilot grants for established and junior investigators managed by the Resource Allocation Program (RAP), and Core Usage Grants managed by PREMIER. More details are available on the Funding Opportunities page of our website.


Machine Learning in the Genome and Phenome to Understand Complex Traits: Discovery Science for Precision Medicine

Held on January 26, 2018 featuring keynote speaker, Marylyn D. Ritchie, PhD, a professor at Penn State followed by PREMIER members: Jimmie Ye, PhD, Sharon Chung, MD, and Zoe Quandt, MD.  Archived lecture is available here (MyAccess required). You can watch this video to also learn about our Center Cores and Services.